Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2021 | $2.25 → $0.40 | Buy → Neutral | Chardan Capital Markets |
| 11/23/2021 | $7.00 → $2.25 | Buy | Chardan Capital |
Chardan Capital Markets downgraded Exicure from Buy to Neutral and set a new price target of $0.40 from $2.25 previously
Chardan Capital reiterated coverage of Exicure with a rating of Buy and set a new price target of $2.25 from $7.00 previously
HC Wainwright & Co. reiterated coverage of Exicure with a rating of Buy and set a new price target of $6.00 from $8.00 previously
10-Q - EXICURE, INC. (0001698530) (Filer)
8-K - EXICURE, INC. (0001698530) (Filer)
8-K - EXICURE, INC. (0001698530) (Filer)
Exicure, Inc. (NASDAQ:XCUR, the "Company")) releases the following financial results for the fiscal quarter ended March 31, 2025. First Quarter 2025 Financial Results Cash Position: Cash and cash equivalents were $10.4 million as of March 31, 2025, as compared to $12.5 million as of December 31, 2024. Research and Development (R&D) Expense: Research and development expenses were $0.8 million for the quarter ended March 31, 2025, as compared to $0 for the quarter ended March 31, 2024. The increase in R&D expense of $0.8 million for the three months ended March 31, 2025 was due to incurring research and development expenses in 2025 after the acquisition of GPCR Therapeutics USA Inc. ("G
Exicure, Inc. ("Exicure" or the "Company") (NASDAQ:XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2025 notifying the Company that, as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q by May 20, 2025 for the quarterly period ended March 31, 2025 (the "Form 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange Commission (the "SEC"). Under Nasdaq's listing rules, Exicure has 60 calendar days to submit a plan to regain compliance. If the plan
Topline results expected H2 2025 Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced it has completed patient enrollment in its ongoing Phase 2 clinical trial (NCT05561751) evaluating the safety and efficacy of GPC-100 (burixafor) in combination with propranolol and G-CSF in multiple myeloma patients undergoing autologous stem cell transplant (ASCT). The randomized, open-label, multicenter study is designed to assess whether GPC-100, a small molecule CXCR4 antagonist, can improve CD34+ hematopoietic stem cell mobilization from the bone marrow into the peripheral blood, where they can be collected via leukaph
4 - EXICURE, INC. (0001698530) (Issuer)
4 - EXICURE, INC. (0001698530) (Issuer)
3 - EXICURE, INC. (0001698530) (Issuer)
Exicure, Inc. (NASDAQ:XCUR, "the Company", "Exicure")), today announced that in connection with the change of control transaction approved by the stockholders at the Special Meeting of the Stockholders on December 17, 2024 (the "Change of Control"), the stockholders of the Company approved a second investment of $8.7 million from HiTron Systems Inc. ("HiTron"), a publicly listed company (KOSPI) in South Korea. This investment is expected to close within a few days depending on regulatory approvals. Also, on December 19, 2024, the Board of Directors (the "Board") of the Company changed the authorized number of directors comprising the Board to nine directors and appointed four new directors
Exicure, Inc. (NASDAQ:XCUR), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, today announced that, effective as of August 21, 2023, Paul Kang, a Class III director, was appointed as Chief Executive Officer of the Company and Jiyoung Hwang, a Class I director, was appointed as Chief Financial Officer of the Company. Mr. Kang and Ms. Hwang succeed Mr. Jung-Sang (Michael) Kim, who stepped down as Chief Executive Officer and Chief Financial Officer last Friday. Additionally, effective as of August 21, 2023, the Board also approved the appointment of Hyuk Joon (Raymond) Ko as a Class III direct
Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company"), historically an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets, previously announced an ongoing strategy to explore strategic alternatives to maximize stockholder value, and as part of such ongoing effort, previously announced the appointment of Jung Sang (Michael) Kim as Chief Executive Officer and Chief Financial Officer of the Company and a Class II director of the Company's board of directors (the "Board"). The Company today announced that the Board fully supports the strategic vision of Mr. Kim and his ongoing efforts to maximize stockholder v
4 - EXICURE, INC. (0001698530) (Issuer)
4 - EXICURE, INC. (0001698530) (Issuer)